{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:51Z","timestamp":1793726031508,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI130186"],"award-info":[{"award-number":["R01AI130186"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ijantimicag.2018.09.018","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T01:54:45Z","timestamp":1538099685000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Antibacterial and antivirulence activities of auranofin against Clostridium difficile"],"prefix":"10.1016","volume":"53","author":[{"given":"Ahmed","family":"AbdelKhalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader S.","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8843-8933","authenticated-orcid":false,"given":"Haroon","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-0458","authenticated-orcid":false,"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0001","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1038\/ctg.2015.24","article-title":"C. difficile infection: changing epidemiology and management paradigms","volume":"6","author":"Vindigni","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"10.1016\/j.ijantimicag.2018.09.018_bib0002","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.09.018_bib0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0897190013499521","article-title":"Epidemiology of Clostridium difficile infection","volume":"26","author":"Depestel","year":"2013","journal-title":"J Pharm Pract"},{"issue":"9491","key":"10.1016\/j.ijantimicag.2018.09.018_bib0004","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(05)67420-X","article-title":"Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe","volume":"366","author":"Warny","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.09.018_bib0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4161\/gmic.2.4.16109","article-title":"Both, toxin A and toxin B, are important in Clostridium difficile infection","volume":"2","author":"Kuehne","year":"2011","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.09.018_bib0006","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.mimet.2011.07.017","article-title":"Sporulation studies in Clostridium difficile","volume":"87","author":"Burns","year":"2011","journal-title":"J Microbiol Methods"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.09.018_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","article-title":"Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence","volume":"40","author":"Vardakas","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2018.09.018_bib0008","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.09.018_bib0009","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/antibiotics4030267","article-title":"Antimicrobial resistance and reduced susceptibility in> Clostridium difficile: potential consequences for induction, treatment, and recurrence of C. difficile infection","volume":"4","author":"Baines","year":"2015","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0010","doi-asserted-by":"crossref","first-page":"11596","DOI":"10.1038\/srep11596","article-title":"Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections","volume":"5","author":"Thangamani","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0011","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmicb.2015.00750","article-title":"Repurposing celecoxib as a topical antimicrobial agent","volume":"6","author":"Thangamani","year":"2015","journal-title":"Front Microbiol"},{"issue":"28","key":"10.1016\/j.ijantimicag.2018.09.018_bib0012","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.2174\/1381612821666150506154434","article-title":"Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections","volume":"21","author":"Younis","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.09.018_bib0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R D"},{"issue":"6A","key":"10.1016\/j.ijantimicag.2018.09.018_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0002-9343(83)90481-3","article-title":"Biologic actions and pharmacokinetic studies of auranofin","volume":"75","author":"Walz","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0015","unstructured":"(CLSI), C.a.L.S.I., Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 8th Edition. M11-A8. 2012."},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.09.018_bib0016","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jac\/dkp042","article-title":"Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model","volume":"63","author":"Ochsner","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.09.018_bib0017","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/AAC.01830-13","article-title":"In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.09.018_bib0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/gut.38.3.337","article-title":"Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment","volume":"38","author":"Mahida","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0019","unstructured":"Institute, C.a.L.S., Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u2014Ninth Edition, M07-A9. 2012."},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.09.018_bib0020","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1038\/s41598-018-26674-0","article-title":"Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci","volume":"8","author":"AbdelKhalek","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0021","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1021\/acs.jmedchem.6b01780","article-title":"Phenylthiazole antibacterial agents targeting cell wall synthesis exhibit potent activity in vitro and in vivo against vancomycin-resistant Enterococci","volume":"60","author":"Mohammad","year":"2017","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.09.018_bib0022","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dks450","article-title":"Fidaxomicin inhibits toxin production in Clostridium difficile","volume":"68","author":"Babakhani","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijantimicag.2018.09.018_bib0023","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1128\/AAC.00211-16","article-title":"Evaluating the effects of surotomycin treatment on Clostridium difficile toxin A and B production, immune response, and morphological changes","volume":"60","author":"Endres","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0024","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-60327-365-7_9","article-title":"Human intestinal epithelial response(s) to Clostridium difficile","volume":"646","author":"Jafari","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.09.018_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/1756283X12454590","article-title":"The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?","volume":"6","author":"Bien","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.09.018_bib0026","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/cid\/cis495","article-title":"Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing","volume":"55","author":"Orenstein","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.09.018_bib0027","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ijantimicag.2018.09.018_bib0028","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2174\/1381612823666170209154745","article-title":"In vitro screening of an FDA-Approved library against ESKAPE pathogens","volume":"23","author":"Younis","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.ijantimicag.2018.09.018_bib0029","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.ijantimicag.2018.02.003","article-title":"Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci","volume":"51","author":"Mohammad","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0030","doi-asserted-by":"crossref","first-page":"16407","DOI":"10.1038\/srep16407","article-title":"Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent","volume":"5","author":"Thangamani","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fcimb.2017.00004","article-title":"Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway","volume":"7","author":"Thangamani","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.09.018_bib0032","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00775-009-0466-z","article-title":"Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct","volume":"14","author":"Jackson-Rosario","year":"2009","journal-title":"J Biol Inorg Chem"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.09.018_bib0033","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/gmic.19399","article-title":"Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response","volume":"3","author":"Vedantam","year":"2012","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.09.018_bib0034","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1128\/aem.38.4.637-641.1979","article-title":"Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation","volume":"38","author":"Onderdonk","year":"1979","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.09.018_bib0035","doi-asserted-by":"crossref","first-page":"22571","DOI":"10.1038\/srep22571","article-title":"Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens","volume":"6","author":"Thangamani","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.09.018_bib0036","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijantimicag.2015.12.016","article-title":"Repurposing auranofin for the treatment of cutaneous staphylococcal infections","volume":"47","author":"Thangamani","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.ijantimicag.2018.09.018_bib0037","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/cid\/cir643","article-title":"Relapse versus reinfection: surveillance of Clostridium difficile infection","volume":"53","author":"Kamboj","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.09.018_bib0038","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tim.2014.04.003","article-title":"Clostridium difficile spore biology: sporulation, germination, and spore structural proteins","volume":"22","author":"Paredes-Sabja","year":"2014","journal-title":"Trends Microbiol"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.09.018_bib0039","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00090-08","article-title":"Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease","volume":"52","author":"Al-Nassir","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.09.018_bib0040","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1128\/AAC.01923-15","article-title":"Cadazolid does not promote intestinal colonization of vancomycin-resistant enterococci in mice","volume":"60","author":"Seiler","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:32:53Z","timestamp":1760376773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918302772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0924857918302772"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.018","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibacterial and antivirulence activities of auranofin against Clostridium difficile","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}